# The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

> **NCT05919147** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pennington Biomedical Research Center** · enrollment: 24 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Pioglitazone 45 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05919147
- **Lead sponsor:** Pennington Biomedical Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-03
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919147, "The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05919147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*